Variable | No. of patients(n = 191) | Pre-operative DTC status | P-values | |
---|---|---|---|---|
Positive (n = 30) | Negative (n = 161) | |||
Age (%) | 0.028 | |||
  < =55 years | 94 | 9 (10) | 85 (90) |  |
  > 55 years | 97 | 21 (22) | 76 (78) |  |
Lymph node status (%) | 0.016 | |||
 pN0 | 133 | 15 (11) | 118 (89) |  |
 pN1–2 | 58 | 15 (26) | 43 (74) |  |
Tumor size (%) | 0.816 | |||
 pT1 | 145 | 22 (15) | 123 (85) |  |
 pT2–4 | 46 | 8 (17) | 38 (83) |  |
Tumor grade (%) | 0.421 | |||
 1 | 67 | 8 (12) | 59 (88) |  |
 2 | 75 | 15 (20) | 60 (80) |  |
 3 | 46 | 7 (15) | 39 (85) |  |
 Unknown | 3 |  |  |  |
Estrogen receptor status (%) | 0.612 | |||
 ER positive | 152 | 23 (15) | 129 (85) |  |
 ER negative | 36 | 7 (19) | 29 (81) |  |
 Unknown | 3 |  |  |  |
Progesterone receptor status (%) | 0.549 | |||
 PgR positive | 91 | 13 (14) | 78 (86) |  |
 PgR negative | 91 | 17 (19) | 74 (81) |  |
 Unknown | 9 |  |  |  |
Histological type (%) | 0.088 | |||
 Ductal | 151 | 20 (13) | 131 (87) |  |
 Lobular | 22 | 7 (32) | 15 (68) |  |
 Other | 18 | 3 (17) | 15 (83) |  |
MAI status (%) | 0.678 | |||
 High MAI (≥10) | 60 | 11 (18) | 49 (82) |  |
 Low MAI (<  10) | 119 | 19 (16) | 100 (84) |  |
Adjuvant therapy (%) | 0.029 | |||
 Chemotherapy | 21 | 4 (19) | 17 (81) |  |
 Endocrine therapy | 25 | 9 (36) | 16 (64) |  |
 Chemo- and endocrine therapy | 32 | 3 (9) | 29 (91) |  |
 No therapy | 113 | 14 (12) | 99 (88) |  |